Important aspects related to diet and lifestyle in the new guidelines
EAS Academy, Gabriele Riccardi, 285189
Management of dyslipidaemias in different clinical settings
EAS Academy, Olov Wiklund, 285188
The approach of high - and very high risk patients in the new guidelines
EAS Academy, Lale Tokgozoglu, 285187
New recommendations and concepts in the new guidelines
EAS Academy, Alberico Catapano, 285186
Bempedoic acid : Mechanism of action
EAS Academy, Alberico Catapano, 282694
The clinical experience
EAS Academy, Maciej Banach, 282695
Current available therapies: Ezetimbe
EAS Academy, Alberico Catapano, 282690
Current available therapies: Omega3 & fibrates
EAS Academy, Maciej Banach, 282692
Current available therapies: Statins
EAS Academy, Jan Borén, 282693
Mendelian randomization
EAS Academy, Brian A. Ference, 282689
Guidelines: The goals why?
EAS Academy, Alberico Catapano, 282684
Guidelines: Diabetic patients
EAS Academy, Brian A. Ference, 282686
Guidelines: FH patients
EAS Academy, Jan Borén, 282687
The new guidelines for dyslipidaemia
EAS Academy, Heinz Drexel, 282683
CV disease risk classification
EAS Academy, Lale Tokgozoglu, 282682
Lipoprotein metabolism & the casual role of LDL in Atherosclerosis
EAS Academy, Jan Borén, 282681
Course presentations: An Introduction to Clinical Lipidology, October 2019
EAS Academy, Lale Tokgozoglu, 282679
An Introduction to Clinical Lipidology
EAS Academy, Lale Tokgozoglu, 276242
Lessons from epidemiology and environmental CVD risk factors
EAS Academy, Salim Yusuf, 276243
Overview of the role of lipids in atherosclerosis
EAS Academy, Petri Kovanen, 276244
Genetic disorders of lipid metabolism – with special focus on familial hypercholesterolaemia
EAS Academy, Kees Hovingh, 276245
THE HDL STORY: TIME TO RECONSIDER?
EAS Academy, John Chapman, 272735
NEW LIPID DRUGS: IS LDL DONE, READY FOR NEW TARGETS?
EAS Academy, Erik Stroes, 272734
THE IMMUNE SYSTEM: THE NEXT GAME-CHANGER?
EAS Academy, Matthias Nahrendorf, 272733
SYSTEM-LEVEL ANALYSES OF INFLAMMATORY AND REPAIR MACROPHAGES REVEAL AN INTEGRATED CIRCUITRY OF LIPID AND EPIGENOMIC CHANGES
EAS Academy, Laszlo Nagy, 272732
CLINICAL EXPERIENCE WITH BEMPEDOIC ACID
EAS Academy, Christie Ballantyne, 272731
PHARMACOLOGY OF BEMPEDOIC ACID
EAS Academy, Giuseppe Danilo Norata, 272730
THE GENETIC EVIDENCE FOR INHIBITING THE CHOLESTEROL SYNTHESIS PATHWAY TO CONTROL LDL CHOLESTEROL
EAS Academy, Brian A. Ference, 272729
A DEEP LOOK TO THE RESULTS OF ODYSSEY OUTCOMES
EAS Academy, J. Wouter Jukema, 272722
REDUCE-IT: AN IN DEPTH ANALYSIS
EAS Academy, Christie Ballantyne, 272725
PCSK9 INHIBITION IN CLINICAL PRACTICE
EAS Academy, Francois Mach, 272721
OMEGA 3 AND CV BENEFIT A REVIEW OF THE CLINICAL TRIALS
EAS Academy, Aldo Pietro Maggioni, 272724
HOW GOOD ARE WE IN REACHING THE GOALS?
EAS Academy, Guy de Backer, 272720
OMEGA 3 FATTY ACIDS: BIOLOGICAL FUNCTIONS
EAS Academy, Alexandros Tselepis, 272723
The metabolic basis of FCS
EAS Academy, Stefano Romeo, 272726
Microbiome: A New Theory of Atherosclerosis?
EAS Academy, Thomas Luscher, 272719
Risk Prediction for Add on Lipid Modulating Therapy
EAS Academy, Kausik Ray, 272718
ESTIMATING RISK: WHAT’S NEW?
EAS Academy, Ian Graham, 272717
THE GENETIC BURDEN IN CVD
EAS Academy, Heribert Schunkert, 272716
BIOMARKERS PREDICTING CVD
EAS Academy, Chris Packard, 272715
WHAT IS THE EVIDENCE FOR UPFRONT COMBINATION?
EAS Academy, Michel Farnier, 272708
COMPLEX CASES IN LIPID LOWERING TREATMENT: ONE SIMPLE HIGH INTENSITY CHOLESTEROL LOWERING APPROACH FITS THEM ALL
EAS Academy, Arman Postadzhiyan, 272714
REALITY CHECK: CAN WE GET TO GUIDELINE RECOMMENDED TARGETS?
EAS Academy, Kornelia Kotseva, 272707
OPTIMISING CHOLESTEROL LOWERING TREATMENT: HOW MANY TIMES DO WE LEARN THE SAME LESSON?
EAS Academy, Luis Masana, 272713
CURRENT EVIDENCE FOR LDL CAUSALITY; GOALS AND TARGETS
EAS Academy, Chris Packard, 272706
THE CRITICALITY OF LDL GOAL ATTAINMENT
EAS Academy, Maciej Banach, 272712
Inflammation, Inhibition and Atherothrombosis
EAS Academy, Paul Ridker, 272705
Modified lipids and lipoproteins
EAS Academy, Joseph L. Witztum, 272704
Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis
EAS Academy, Jan Borén, 272703
CARDIOVASCULAR AGING AND MITOCHONDIA FUNCTION
EAS Academy, Douglas Seals, 272701
A Journey From Plaque to Pate
EAS Academy, Helen Hobbs, 272699
PHYSICIAN-PATIENT RELATIONSHIP: CHALLENGES AND OPPORTUNITIES
EAS Academy, Lale Tokgozoglu, 272697
OPTIMAL LIPID LOWERING THERAPY: NEW AND ESTABLISHED THERAPIES
EAS Academy, Christie Ballantyne, 272696
WHAT IS THE PRICE TO PAY IF WE ARE NOT AT GOAL?
EAS Academy, Alberto Zambon, 272695
EFFICACY AND SAFETY OF NUTRACEUTICALS
EAS Academy, Maciej Banach, 272694
POSSIBILITIES FOR NUTRIGENETICS AND NUTRACEUTICALS IN CVD PREVENTION
EAS Academy, Jogchum Plat, 272693
DIFFERENT APPROACHES TO LDL LOWERING: AN OVERVIEW OF OPTIONS INCLUDING NUTRITION, FOOD SUPPLEMENTS, AND DRUG THERAPY
EAS Academy, John Chapman, 272692
EAS Certificate of Excellence in Clinical Lipidology
EAS Academy, Course Faculty, 258508
Adaptive Immunity: T cells and B cells
EAS Academy, Ziad Mallat, 234784
Innate immunity: Inflammasome
EAS Academy, Eicke Latz, 234783
Regulation of lipid metabolism by inflammation
EAS Academy, Laurent Yvan-Charvet, 234782
LDL retention
EAS Academy, Jan Borén, 234781
2016 ESC/EAS guidelines for the management of dyslipidaemias-risk prediction and treatments targets
EAS Academy, Olov Wiklund, 233810
New and old lipid-lowering drugs
EAS Academy, Lale Tokgozoglu, 233809
What have Mendelian Randomization studies revealed for cardiovascular disease beyond lipids?
EAS Academy, Marianne Benn, 233808
Causality of lipid traits for other diseases
EAS Academy, Ruth Frikke-Schmidt, 233807
The case of lipoprotein(a) and cardiovascular disease
EAS Academy, PIA R. KAMSTRUP, 233806
Using genetics to predict drug effects and adverse events
EAS Academy, Anne Tybjaerg-Hansen, 233805
The case for triglyceride-rich lipoproteins and cardiovascular disease
EAS Academy, Borge Nordestgaard, 233804
Concepts of Mendelian randomization
EAS Academy, Shah Ebrahim, 233803
MODULE 6: FAMILIAL DYSLIPIDAEMIAS
EAS Academy, Course Faculty, 258505
Genetic disorders of lipid metabolism - with special focus on familial hypercholesterolaemia
EAS Academy, Kees Hovingh, 233802
Biology of lipid metabolism
EAS Academy, Patrick Rensen, 233801
Global burden of cardiovascular disease and contribution of risk factors
EAS Academy, Gregory Roth, 233800
EAS Clinical Lipidology Essentials
EAS Academy, EAS, 226229
Module 1: Epidemiology. Development of cardiovascular disease in different populations
EAS Academy, Annika Rosengren, 226230
Module 2: Mendelian randomization approach to understand effect of lipoprotein in causing disease
EAS Academy, Anne Tybjaerg-Hansen, 226231
Module 3: Basics in Lipoprotein Metabolism
EAS Academy, Jan Borén, 226232
Module 4: Atherosclerosis: update on the pathophysiology: role of LDL
EAS Academy, Petri Kovanen, 226233
Strategies to treat vulnerable plaques
EAS Academy, David Erlinge, 217777
Novel therapeutic approaches using antisense inhibition (TBD)
EAS Academy, Joseph L. Witztum, 217776
Lessons from genetics: risk-score and novel candidates
EAS Academy, Brian A. Ference, 217775
Atherothrombosis; from pathogenesis to treatment
EAS Academy, Steffen Massberg, 217774
NOVEL ROLE OF A TRIGLYCERIDE-SYNTHESIZING ENZYME: DGAT1 AT THE CROSSROAD BETWEEN TRIGLYCERIDE AND CHOLESTEROL METABOLISM
EAS Academy, Vinay Sachdev, 217771
GENETIC REGULATION OF HDL CHOLESTEROL LEVELS DURING SEPSIS
EAS Academy, Liam Brunham, 217769
Lipid Signaling pathways in physiology and disease
EAS Academy, Peter Tontonoz, 217768
The role of bile acids in cholesterol homeostasis
EAS Academy, Albert K. Groen, 217767
Panel Discussion
EAS Academy, Session Speakers, 218366
The ideal patient for PCSK9
EAS Academy, J. Wouter Jukema, 217755
Combination therapy: When and how
EAS Academy, Michel Farnier, 217764
How to control atherogenic dyslipidaemia
EAS Academy, Henry Ginsberg, 217763
Panel Discussion
EAS Academy, Session Speakers, 218372
PCSK9 Inhibition in high risk patients
EAS Academy, Gabriel Steg, 217754
Lipids, inflammation and CV risk
EAS Academy, Erik Stroes, 217753
New targets for controlling dyslipidaemias and atherosclerosis: chair
EAS Academy, Paolo Parini, 217757
Silencing genes, new targets
EAS Academy, Sotirios Tsimikas, 217758
APO B CONTAINING LIPOPROTEINS A BETTER TARGET FOR CV RISK REDUCTION?
EAS Academy, Brian A. Ference, 217762
MODULE 2: LIPIDS, LIPOPROTEINS AND METABOLISM
EAS Academy, Course Faculty, 258502
Dysregulation of hepatic and lipoprotein metabolism in the atherogenic dyslipidemia
EAS Academy, Marja-Riitta Taskinen, 217750
Reality check: Can we get to goals in guidelines?
EAS Academy, Ulrich Laufs, 217747

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings